Traws Pharma (NASDAQ:TRAW) shareholders approved all proposals presented at the company’s 2026 Annual Meeting of Stockholders, according to remarks made during the virtual meeting.
Jack Stover, chairman of the board, presided over the meeting alongside Dr. Iain Dukes, chief executive officer of Traws Pharma. Charles Parker, the company’s chief financial officer, served as secretary of the meeting, while Jim Rate of Broadridge acted as inspector of election.
Quorum Established
Parker reported that approximately 8.5 million shares of common stock were represented in person or by proxy, equal to about 56% of the shares entitled to vote at the meeting. Because that exceeded one-third of the shares entitled to vote, Parker said a quorum was present, allowing the meeting to proceed.
Stover said the polls were opened for shareholders who had not yet voted or wished to change their votes. Shareholders who had already submitted proxies or voted by telephone or internet did not need to take further action unless they wanted to change their instructions.
Five Proposals Presented
Dukes began the review of the proposals before Parker continued after audio distortion interrupted the presentation. The company placed five items before shareholders:
- The election of seven directors to serve until the next annual meeting of shareholders and until their successors are duly elected and qualified, subject to earlier departure or removal.
- An amendment to the company’s 2021 Incentive Compensation Plan, as amended and restated, to increase the number of shares of common stock available for issuance by 2 million and make certain other administrative changes.
- The ratification of KPMG LLP as the company’s independent registered public accounting firm for fiscal year 2026.
- The approval of the issuance of shares of common stock upon the exercise of Series B warrants and Series C warrants under a securities purchase agreement entered into on April 15, 2026.
- The authorization of an adjournment of the annual meeting to another place or later date or dates.
Stover asked whether any questions had been submitted regarding the proposals before voting closed. Parker said the company had not received any such questions.
All Proposals Approved
After the polls closed, Rate reported the preliminary voting results. Each of the director nominees was elected. Shareholders also approved the amendment to the 2021 Incentive Compensation Plan, ratified KPMG LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved the issuance of shares upon exercise of the Series B and Series C warrants.
Shareholders also approved the proposal authorizing an adjournment of the annual meeting. However, Rate said he had been advised by Dukes that the meeting would not be adjourned to a later date or time because all other proposals had been approved.
Rate said he would prepare the final report as soon as practical and deliver it to the secretary of the meeting to be filed with the meeting minutes. Stover said the final results would be filed with the Securities and Exchange Commission on Form 8-K within four business days of the meeting.
No Shareholder Questions Submitted
After the formal portion of the meeting was adjourned, Stover invited shareholder questions. Parker said no questions had been received.
Stover thanked shareholders for attending the virtual meeting and for their interest in the company. The meeting then concluded.
About Traws Pharma (NASDAQ:TRAW)
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
